Immunotherapy plus radiation for advanced head and neck cancer
Part of Cancer, Ear, nose & throat clinical trials.
This trial tests a combination of an immunotherapy drug (sintilimab) with radiation and chemotherapy for people with advanced head and neck cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a confirmed diagnosis of stage III or IVB head and neck squamous cell carcinoma.
- You must not have had prior systemic treatment (like chemotherapy or immunotherapy) for this cancer.
- You must be in generally good health, with adequate organ function (kidney, liver, blood).
- You must not have certain heart conditions, active infections, autoimmune diseases, or other cancers.
- You must agree to use effective contraception if you are of childbearing potential.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an immune checkpoint inhibitor (a drug that helps your immune system fight cancer) as maintenance therapy after chemoradiotherapy improves outcomes for people with locally advanced head and neck cancer. It specifically looks at a marker in your blood (CD8Tex cells) to see if you might benefit.
This trial compares giving immunotherapy alone versus immunotherapy plus focused radiation before surgery for head and neck cancer. The goal is to see if adding radiation helps shrink the tumor and improve outcomes.
This trial tests whether giving an immunotherapy drug called sintilimab before and after surgery can help treat head and neck cancer. The drug aims to boost your immune system to fight the cancer, and the goal is to improve outcomes when combined with the standard surgical treatment.
This trial tests a combination of two immunotherapy drugs (IBI110 and sintilimab) with chemotherapy before surgery for people with advanced head and neck cancer that can be removed surgically. The goal is to see if this approach helps shrink tumors and improve outcomes.
This trial tests whether combining two medicines – sintilimab (an immunotherapy) and cetuximab (a targeted therapy) – given before and after surgery can help treat advanced mouth or throat cancer. The study aims to see if this approach is safe and effective for patients whose cancer has not spread.
This Phase 2 study tests whether tislelizumab (an immunotherapy) combined with chemotherapy works better for locally advanced head and neck squamous cell cancer. It aims to improve cancer control when the tumor is large and has not spread to distant organs.
Hear when a new Locally Advanced Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.